Bio-Hermes-002

Diagnosing the disease can be expensive, invasive and complicated. Research in RI could help speed up the process Feb. 5, 2026, 5:04 a.m. ETEAST PROVIDENCE – Alzheimer’s, a neurodegenerative disease, is the primary cause of dementia in the United States. In Rhode Island, more than one in 10 adults over age 65 – about 22,000 […]

Alzheimer’s disease study brings new testing to Las Vegas Courtesy Axiom Brain Health’s Kaden Appleberry processes lab sample for study. By Katie Ann McCarver (contact) Monday, January 26, 2026 – 2 a.m. A Las Vegas stronghold in neurology is contributing to a new study spanning multiple states and countries related to the detection and diagnosis of Alzheimer’s disease. Clinical Neurology […]

by News 3 Staff,Updated Fri, January 23, 2026 at 1:20 PM LAS VEGAS (KSNV) — Clinical Neurology Specialists (CNS) in Las Vegas is participating in a groundbreaking international study sponsored by the Global Alzheimer’s Platform Foundation. The Bio-Hermes-002 study seeks volunteers with memory concerns to help identify blood or digital tests that could predict the presence of amyloid […]

Jan 20, 2026 | staff reporterSave for later NEW YORK — UK nonprofit research organization LifeArc said on Monday that it has partnered with the Global Alzheimer’s Platform Foundation (GAP) to evaluate a blood-based test for Alzheimer’s disease. The test is designed to detect three proteins — phosphorylated tau 217, glial fibrillary acidic protein, and neurofilament light […]

The test aims to pick up three proteins known to be associated with Alzheimer’s Jane KirbyMonday 19 January 2026 11:14 GMT Bookmark popover Removed from bookmarksClose popover A pioneering trial has begun to assess whether a simple finger-prick blood test could offer an early diagnosis for Alzheimer’s disease, even before symptoms manifest. Experts are optimistic […]

A major international research project is underway to test whether a finger prick-style blood test could be used to help diagnose Alzheimer’s disease. The trial is looking at three proteins in the blood that are associated with Alzheimer’s and comparing this with the current gold standard approach to diagnosing the disease that uses expensive brain […]

  By Jacquelyn Voghel 01/18/2026 EAST PROVIDENCE – A national research institution’s Rhode Island location is calling for volunteers with Alzheimer’s disease to participate in a study attempting to identify predictive markers of the brain condition. K2 Medical Research – East Providence has begun enrolling participants in the Bio-Hermes 002 Study, an initiative of the Global Alzheimer’s Platform Foundation. The study seeks […]

Spear Bio joins collaborative study focused on new biomarkers designed to improvediagnosis of Alzheimer’s disease and dementias  Washington D.C., Jan 12, 2026 – The Global Alzheimer’s Platform Foundation® (GAP) is pleased to welcome Spear Bio, a biotechnology company pioneering wash-free ultrasensitive immunoassay technology, to the Bio-Hermes-002 study. This collaboration will enhance this unique, observational platform […]

Washington D.C., Jan 9, 2026 – The Global Alzheimer’s Platform Foundation® (GAP) is pleased to welcome Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, to the Bio-Hermes studies. This collaboration will enhance the unique, observational platform studies that compare blood-based and digital biomarkers across a broad range of clinical […]

Collaboration to Improve Access to Study for Alzheimer’s Disease Las Vegas, Nev. – Dec. 23 2025 – Today, Global Alzheimer’s Platform Foundation® (GAP) and Clinical Neurology Specialists (CNS) announced their collaboration to accelerate Alzheimer’s disease research in Las Vegas. CNS has joined the GAP-sponsored study, Bio-Hermes-002, a unique, observational platform study that compares blood-based and digital biomarkers […]

Posted on October 2, 2025 • by Julia Ferrar Most biomarker tests, such as PET scans and spinal taps, are expensive or invasive and can pose risks for patients. That’s why a company in the Tampa Bay area is helping to research blood tests for biomarkers as a less expensive and more accessible alternative. Axiom […]

Prevent cognitive decline with these proven lifestyle changes! Join us on PSI TV as Dr. Susan Steen, MD, a renowned neurologist and Alzheimer’s expert, shares groundbreaking insights into brain health. Representing Axiom Brain Health, Dr. Steen discusses their mission to combat neurodegenerative diseases like Alzheimer’s and Parkinson’s through cutting-edge research and clinical trials. Learn how […]

trialsitenews, Aug. 28, 2025, 12:30 p.m. September is Alzheimer’s Awareness Month, a time to reflect on the devastating impact of Alzheimer’s disease and the urgent need for better treatments and care. More than 6 million Americans are living with Alzheimer’s, a number expected to climb steeply in the coming decades. As the need grows, so […]

IXICO joins collaborative study of new biomarkers designed to improve diagnosis of Alzheimer’s disease and dementias  Washington D.C., July 22, 2025 – The Global Alzheimer’s Platform Foundation® (GAP) is pleased to welcome IXICO, a global leader in neuroscience imaging and biomarker analytics, to the Bio-Hermes-002 study. This collaboration will enhance this unique, observational platform study […]

iLoF, the leading innovator in AI-powered photonics platforms for personalised medicine, announces today a strategic investment from Hamamatsu, the world expert in the development and manufacturing of photonics devices and systems for medical optics and biophotonics, to further its mission of transforming healthcare and driving innovation in medicine. LONDON, Oct. 22, 2024 /PRNewswire/ — iLoF, the leading company […]

The free clinical trial at Axiom Brain Health in Tampa works to detect early signs of Alzheimer’s and other cognitive diseases, even years before symptoms appear. Author: Hannah Dineen Published: 4:04 PM EST March 6, 2025 Updated: 8:52 PM EST March 6, 2025 TAMPA, Fla. — It’s estimated nearly 7 million people in the U.S. are living with Alzheimer’s disease. […]

Washington D.C., Feb. 18, 2025 – The Global Alzheimer’s Platform Foundation® (GAP) is pleased to welcome Roche to the Bio-Hermes-002 study. This collaboration will enhance this unique, observational platform study that compares blood-based and digital biomarkers across a broad range of clinical cognitive conditions, MRI and PET images as well as numerous races and ethnicities […]

Washington D.C., Jan. 23, 2025 – The Global Alzheimer’s Platform Foundation® (GAP) is pleased to welcome Beckman Coulter Diagnostics as a strategic partner in the Bio-Hermes-002 study. This first-time collaboration will enhance this unique, observational platform study that compares blood-based and digital biomarkers across a broad range of clinical cognitive conditions, MRI and PET images […]

By Austin Montgomery| December 11, 2024 Global Alzheimer’s Platform Foundation (GAP) has partnered with Eli Lilly and Company (NYSE: LLY) for a study comparing blood tests that could help predict and diagnose Alzheimer’s disease. The Bio-Hermes-002 study looks to increase participation of underrepresented older adults within typical Alzheimer’s clinical research, with at least 25% participation earmarked […]

The Global Alzheimer’s Platform Foundation (GAP) is excited to announce its collaboration with Eli Lilly and Company on the transformative Bio-Hermes-002 study. This partnership is poised to broaden the understanding of Alzheimer’s disease by integrating advanced biomarkers that may assist in its early detection and diagnosis. Significance of the Bio-Hermes-002 Study Like its predecessor, Bio-Hermes-001, […]

ViewMind Precision Neurological Assessments ViewMind Digital BiomarkerPublished 7:31 AM EST, December 10, 2024Share To Enhance Alzheimer’s Diagnosis Through Diverse Biomarker Analysis “We expect ViewMind’s promising technology to offer the field alternative methods for detecting and diagnosing Alzheimer’s disease.”— John Dwyer, President of the Global Alzheimer’s Platform Foundation NEW YORK CITY, NY, UNITED STATES, December 10, […]

Washington D.C., Dec. 9, 2024 – The Global Alzheimer’s Platform Foundation® (GAP) is pleased to welcome Eli Lilly and Company (Lilly) to the Bio-Hermes-002 study. This collaboration will enrich the unique, observational platform study that compares blood-based and digital biomarkers across a broad range of races and ethnicities that may help predict and diagnose Alzheimer’s […]

Contify Life Science News Nov 3 • 11:52 PM *Cognivue’s participation in the study will help predict underlying AD pathologies and analyze MRI, neuroinflammation, and longitudinal data. Oct. 30– Cognivue issued the following news release:. Its proven ability to distinguish between cognitively normal individuals, those with MCI, and mild dementia— regardless of amyloid status., Validated […]

Oct 30, 2024 | staff reporterSave for later NEW YORK – The Global Alzheimer’s Platform (GAP) Foundation has launched the Bio-Hermes-002 study, in which it will continue to explore biomarkers that can predict the likelihood that a patient has amyloid and tau accumulations in their brains, signaling a potential Alzheimer’s diagnosis. The Alzheimer’s research-focused nonprofit announced the […]